OrR reached 86% of patients with specific non-small cell lung cancer with positive clinical results for next-generation precision therapy.

The development of precision therapies with targeted drivers is becoming one of the most important strategies in the development of anticancer therapies by analyzing the genetic variation that drives tumor progression.
, for example, Roche's Rozlytrek, which targets THES1 and NTRK gene fusion, received FDA accelerated approval last year to treat NSCLC patients with ROS1 gene mutations and solid tumor patients with NTRK fusion.
repotrectinib is a broad-spectrum next-generation TKI that inhibits the activity of ROS1, TRK and ARK.
it has the potential to treat ROS1-positive NSCLC, as well as ROS1, NTRK, and ARK-positive solid tumors, by overcoming a variety of gene mutations that are resistant to other TKI, killing multiple tumor cells that carry the fusion of the ROS1 or NTRK genes.
in TRIDENT-1 clinical trials, repotrectinib treats different types of NSCLC and solid tumor patients as a single drug.
test results showed that in patients with ROS1-positive NSCLC who had never been treated with TKI, repotrectinib achieved an objective remission rate (ORR) of 86% (6/7).
patients were also partially unconfirmed and were still receiving treatment after the data deadline.
40% (2/5) of NSCLC patients who tested positive for ROS1, received a pre-TKI treatment, and received chemotherapy.
NTRK-positive, TKI treated solid tumor patients, ORR reached 50% (3/6).
detailed efficacy data from phase 1 and Phase 2 clinical trials (Photo: Source: References) References: s1 Turning Point Therapeutics Reports Early Interim Data From RegistrationAl Phase 2 Trident-1 Study of Repotrectinib, Provides Regulatory Update. Retrieved August 19, 2020, from.